Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still
expanding. This group is very diverse in terms of peptide size. It contains very small …

Receptor targeting with radiolabelled peptides has become very important in nuclear
medicine and oncology in the past few years. The overexpression of many peptide receptors …

Receptor targeting with radiolabeled peptides has become an important topic, particularly in
nuclear oncology. Strong research efforts are under way in radiopharmaceutical science …

We recently introduced the potent gastrin-releasing peptide receptor (GRPR) antagonist
68Ga-SB3 (68Ga-DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly …

Purpose: G protein–coupled receptor agonists are being used as radiolabeled vectors for in
vivo localization and therapy of tumors. Recently, somatostatin-based antagonists were …

Because overexpression of the gastrin-releasing peptide receptor (GRPR) has been
reported on various cancer types, for example, prostate cancer and breast cancer, targeting …

Ex vivo studies have shown that the gastrin releasing peptide receptor (GRPr) is
overexpressed on almost all primary prostate cancers, making it a promising target for …

Targeted radionuclide therapy has become increasingly prominent as a nuclear medicine
subspecialty. For many decades, treatment with radionuclides has been mainly restricted to …

Purpose Gastrin-releasing peptide receptors (GRPR) represent attractive targets for tumor
diagnosis and therapy because of their overexpression in major human cancers …